Related Experiment Video
Updated: Dec 28, 2025

11:15
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.6K
Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.
Eric R Molina1, Letitia K Chim1, Sergio Barrios1
1Department of Bioengineering, Rice University, Houston, Texas.
Tissue Engineering. Part B, Reviews
|February 15, 2020
Summary
Tissue engineering advances preclinical cancer models by incorporating the tumor microenvironment. This approach aims to improve the translation of research findings for osteosarcoma and Ewing sarcoma to clinical trials.
Area of Science:
- Oncology
- Tissue Engineering
- Biomedical Engineering
Background:
- Current cancer research relies on outdated monolayer cell cultures, failing to replicate the complex tumor microenvironment.
- This limitation hinders the accurate prediction of therapeutic efficacy and patient outcomes.
- Osteosarcoma (OS) and Ewing sarcoma (ES) patient outcomes have stagnated due to inadequate preclinical models.
Purpose of the Study:
- To review the clinical aspects of OS and ES.
- To identify critical elements of the bone tumor microenvironment.
- To explore tissue engineering approaches for modeling the bone tumor microenvironment.
Main Methods:
- Review of clinical data for OS and ES.
- Analysis of key components within the bone tumor microenvironment.
- Examination of tissue engineering strategies for creating advanced preclinical models.
Main Results:
- Traditional cell culture models lack essential tumor microenvironment factors.
- Tissue engineering offers methods to incorporate physical and biological elements into models.
- These advanced models better represent the in vivo tumor context.
Conclusions:
- Tissue engineering provides novel in vitro models for bone sarcomas.
- Incorporating the tumor microenvironment is crucial for accurate preclinical research.
- Improved models can enhance the development of effective cancer therapeutics.

